Novartis' latest Zolgensma data bode well for use in older patients

Novartis is aiming to steal share in spinal muscular atrophy with its new gene therapy Zolgensma, and it's already won approval for patients under 2. Now, the company is touting data showing dramatic improvements after treatment for patients between 2 and 5.